Latest news
Debiopharm Launches Phase 1/2 Combination Trial Investigating Brain-Penetrant Selective WEE1 Inhibitor for Brain Cancer Patients
Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
Debiopharm Announces Launch of the Phase 1/2 GaLuCi Study for its CA IX-Targeted Radiopharmaceutical Program
Iktos announces closing of € 15.5M series A round co-led by M Ventures and Debiopharm
Debiopharm extends their DNA damage repair footprint with new oncology pipeline entry
Challenge pour la Qualité de vie du patient 2023 : l’appel à projets est ouvert !
Debiopharm Applies Extended-Release Formulation Expertise To Reduce Treatment Frequency Burden For Acromegaly & GEP-NET Patients
Le 7e Challenge Qualité de vie du patient récompense le dispositif de massage MRM destiné aux personnes en fauteuil roulant,…
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.